More on TAK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $19.05 |
|
|||
| Open | $18.80 | ||||
| 52 Wk High | $0.55 | ||||
| 52 Wk Low | $0.55 | ||||
| Day High | $19.01 | ||||
| Day Low | $18.80 | ||||
| P/E | N/A | ||||
| EPS | $-0.20 | ||||
| Volume | 2,960,710 | ||||
- Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY7,000 at Nomura/Instinet
- Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
- Form 4 TAKEDA PHARMACEUTICAL For: Sep 14 Filed by: Duprey Lauren Rusckowski
- Form 6-K TAKEDA PHARMACEUTICAL For: Sep 14
- FDA accepts Takeda's zasocitinib drug application for plaque psoriasis
- U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
- NEJM publishes Takeda's phase 3 data on narcolepsy drug oveporexton
- New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
- Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley
Entities mentioned with TAK
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Dividend | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
